In these FHA patients, AMH tends to rise after three months of pulsatile GnRH treatment and this seems to be associated with a rise in FSH, which underlines that the phenomenon of low AMH levels is based on relative gonadotropin deficiency rather than diminished ovarian reserve. The gene discussed is GNRH1; the disease is Gonadotropin deficiency.